J Korean Med Sci.  2023 Apr;38(13):e115. 10.3346/jkms.2023.38.e115.

Clinical Practice Guideline for Gastritis in Korea

• Kang SJ
• Kim JG
• Moon HS
• Kook MC
• Lee JY
• Bang CS
• Tae CH
• Gong EJ
• Nam SY
• Kim HJ
• Korean College of Helicobacter and Upper Gastrointestinal Research

• KMID: 2541046
• DOI: http://doi.org/10.3346/jkms.2023.38.e115

Abstract

Gastritis is a disease characterized by inflammation of the gastric mucosa. It is very common and has various classification systems such as the updated Sydney system. As there is a lot of evidence that Helicobacter pylori infection is associated with the development of gastric cancer and that gastric cancer can be prevented by eradication, H. pylori gastritis has been emphasized recently. The incidence rate of gastric cancer in Korea is the highest in the world, and due to the spread of screening endoscopy, atrophic gastritis and intestinal metaplasia are commonly diagnosed in the general population. However, there have been no clinical guidelines developed in Korea for these lesions. Therefore, this clinical guideline has been developed by the Korean College of Helicobacter and Upper Gastrointestinal Research for important topics that are frequently encountered in clinical situations related to gastritis. Evidence-based guidelines were developed through systematic review and de novo processes, and eight recommendations were made for eight key questions. This guideline needs to be periodically revised according to the needs of clinical practice or as important evidence about this issue is published in the future.

Keyword

Gastritis; Helicobacter pylori; Atrophy; Intestinal Metaplasia

Reference

1. Misiewicz JJ. The Sydney system: a new classification of gastritis. Introduction. J Gastroenterol Hepatol. 1991; 6(3):207–208. PMID: 1912430.

2. ICD-10 version: 2015. Accessed January 20, 2015. https://icd.who.int/browse10/2015/en#/K29 .

3. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015; 64(9):1353–1367. PMID: 26187502.

4. Park HK, Kim N, Lee SW, Park JJ, Kim JI, Lee SY, et al. The distribution of endoscopic gastritis in 25,536 health check-up subjects in Korea. Korean J Helicobacter Up Gastrointest Res. 2012; 12(4):237–243.

5. Kim N, Park YS, Cho SI, Lee HS, Choe G, Kim IW, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter. 2008; 13(4):245–255. PMID: 18665932.

6. Fang JY, Du YQ, Liu WZ, Ren JL, Li YQ, Chen XY, et al. Chinese consensus on chronic gastritis (2017, Shanghai). J Dig Dis. 2018; 19(4):182–203. PMID: 29573173.

7. Oh JH, Kwon JG, Jung HK, Tae CH, Song KH, Kang SJ, et al. Clinical practice guidelines for functional dyspepsia in Korea. J Neurogastroenterol Motil. 2020; 26(1):29–50. PMID: 31917913.

8. Yoon K, Kim N. Significance of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia. Korean J Helicobacter Up Gastrointest Res. 2020; 20(2):107–116.

9. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019; 51(4):365–388. PMID: 30841008.

10. Gupta S, Li D, El Serag HB, Davitkov P, Altayar O, Sultan S, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020; 158(3):693–702. PMID: 31816298.

11. Banks M, Graham D, Jansen M, Gotoda T, Coda S, di Pietro M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019; 68(9):1545–1575. PMID: 31278206.

12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMID: 19622552.

13. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. PMID: 31462531.

14. Hinneburg I. ROBINS-1: a tool for asssessing risk of bias in non-randomised studies of interventions. Med Monatsschr Pharm. 2017; 40(4):175–177. PMID: 29952172.

15. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529–536. PMID: 22007046.

16. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017; 358:j4008. PMID: 28935701.

17. Kim SY, Choi MY, Shin SS. NECA’s Handbook for Clinical Practice Guideline Developer Version 1.0. Seoul, Korea: National Evidence based healthcare Collaborating Agency;2015.

18. Rodríguez-Carrasco M, Esposito G, Libânio D, Pimentel-Nunes P, Dinis-Ribeiro M. Image-enhanced endoscopy for gastric preneoplastic conditions and neoplastic lesions: a systematic review and meta-analysis. Endoscopy. 2020; 52(12):1048–1065. PMID: 32663879.

19. So J, Rajnakova A, Chan YH, Tay A, Shah N, Salto-Tellez M, et al. Endoscopic tri-modal imaging improves detection of gastric intestinal metaplasia among a high-risk patient population in Singapore. Dig Dis Sci. 2013; 58(12):3566–3575. PMID: 23996468.

20. Chen H, Wang H, Wu X, Liu Y, Wu Q, Lu Y, et al. Predictability of gastric intestinal metaplasia by patchy lavender color seen on linked color imaging endoscopy. Lasers Med Sci. 2019; 34(9):1791–1797. PMID: 30903528.

21. Sha J, Wang P, Zhu B, Zhu M, Li X, Gao F. Acetic acid enhanced narrow band imaging for the diagnosis of gastric intestinal metaplasia. PLoS One. 2017; 12(1):e0170957. PMID: 28135297.

22. Chen H, Wu X, Liu Y, Wu Q, Lu Y, Li C. Blue laser imaging with acetic acid enhancement improved the detection rate of gastric intestinal metaplasia. Lasers Med Sci. 2019; 34(3):555–559. PMID: 30191343.

23. Ono S, Kato M, Tsuda M, Miyamoto S, Abiko S, Shimizu Y, et al. Lavender color in linked color imaging enables noninvasive detection of gastric intestinal metaplasia. Digestion. 2018; 98(4):222–230. PMID: 30045046.

24. Eshmuratov A, Nah JC, Kim N, Lee HS, Lee HE, Lee BH, et al. The correlation of endoscopic and histological diagnosis of gastric atrophy. Dig Dis Sci. 2010; 55(5):1364–1375. PMID: 19629687.

25. Lee JY, Kim N, Lee HS, Oh JC, Kwon YH, Choi YJ, et al. Correlations among endoscopic, histologic and serologic diagnoses for the assessment of atrophic gastritis. J Cancer Prev. 2014; 19(1):47–55. PMID: 25337572.

26. Nomura S, Ida K, Terao S, Adachi K, Kato T, Watanabe H, et al. Endoscopic diagnosis of gastric mucosal atrophy: multicenter prospective study. Dig Endosc. 2014; 26(6):709–719. PMID: 24698334.

27. Calle Astudillo G, Jerves T, Pesántez L, Calle P, Gutiérrez A, Calle G. Utility of routine gastric biopsies and staining with methylene blue in the diagnosis of intestinal metaplasia in patients over 40 years. Acta Gastroenterol Latinoam. 2013; 43(3):189–197. PMID: 24303684.

28. Lim JH, Kim N, Lee HS, Choe G, Jo SY, Chon I, et al. Correlation between endoscopic and histological diagnoses of gastric intestinal metaplasia. Gut Liver. 2013; 7(1):41–50. PMID: 23423616.

29. Lin BR, Shun CT, Wang TH, Lin JT. Endoscopic diagnosis of intestinal metaplasia of stomach--accuracy judged by histology. Hepatogastroenterology. 1999; 46(25):162–166. PMID: 10228782.

30. Yue H, Shan L, Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2018; 21(4):579–587. PMID: 29460004.

31. Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010; 71(7):1150–1158. PMID: 20381801.

32. Rugge M, de Boni M, Pennelli G, de Bona M, Giacomelli L, Fassan M, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther. 2010; 31(10):1104–1111. PMID: 20180784.

33. Rugge M, Genta RM, Fassan M, Valentini E, Coati I, Guzzinati S, et al. OLGA gastritis staging for the prediction of gastric cancer risk: a long-term follow-up study of 7436 patients. Am J Gastroenterol. 2018; 113(11):1621–1628. PMID: 30333540.

34. Rugge M, Meggio A, Pravadelli C, Barbareschi M, Fassan M, Gentilini M, et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut. 2019; 68(1):11–17. PMID: 29306868.

35. den Hollander WJ, Holster IL, den Hoed CM, Capelle LG, Tang TJ, Anten MP, et al. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. Gut. 2019; 68(4):585–593. PMID: 29875257.

36. Nieminen AA, Kontto J, Puolakkainen P, Virtamo J, Kokkola A. Comparison of operative link for gastritis assessment, operative link on gastric intestinal metaplasia assessment, and TAIM stagings among men with atrophic gastritis. World J Gastroenterol. 2020; 26(24):3447–3457. PMID: 32655268.

37. Piazuelo MB, Bravo LE, Mera RM, Camargo MC, Bravo JC, Delgado AG, et al. The Colombian chemoprevention trial: 20-year follow-up of a cohort of patients with gastric precancerous lesions. Gastroenterology. 2021; 160(4):1106–1117.e3. PMID: 33220252.

38. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. 2005; 36(3):228–233. PMID: 15791566.

39. Yoon H, Kim N, Lee HS, Shin CM, Park YS, Lee DH, et al. Effect of endoscopic screening at 1-year intervals on the clinicopathologic characteristics and treatment of gastric cancer in South Korea. J Gastroenterol Hepatol. 2012; 27(5):928–934. PMID: 22142434.

40. Chung SJ, Park MJ, Kang SJ, Kang HY, Chung GE, Kim SG, et al. Effect of annual endoscopic screening on clinicopathologic characteristics and treatment modality of gastric cancer in a high-incidence region of Korea. Int J Cancer. 2012; 131(10):2376–2384. PMID: 22362223.

41. Choi IJ, Kim CG, Lee JY, Kim YI, Kook MC, Park B, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 2020; 382(5):427–436. PMID: 31995688.

42. You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006; 98(14):974–983. PMID: 16849680.

43. Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012; 104(6):488–492. PMID: 22271764.

44. Li WQ, Zhang JY, Ma JL, Li ZX, Zhang L, Zhang Y, et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ. 2019; 366:l5016. PMID: 31511230.

45. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut. 2004; 53(9):1244–1249. PMID: 15306578.

46. Zhou L, Lin S, Ding S, Huang X, Jin Z, Cui R, et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chin Med J (Engl). 2014; 127(8):1454–1458. PMID: 24762588.

47. Wong BC, Zhang L, Ma JL, Pan KF, Li JY, Shen L, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut. 2012; 61(6):812–818. PMID: 21917649.

48. Saito D. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. Gastroenterology. 2005; 128(4 Suppl 2):A4.

49. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004; 291(2):187–194. PMID: 14722144.

50. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst. 2000; 92(23):1881–1888. PMID: 11106679.

51. Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000; 119(1):7–14. PMID: 10889149.

52. Kamada T, Haruma K, Hata J, Kusunoki H, Sasaki A, Ito M, et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol Ther. 2003; 18(2):245–252. PMID: 12869086.

53. Cho SJ, Choi IJ, Kook MC, Yoon H, Park S, Kim CG, et al. Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer. Aliment Pharmacol Ther. 2013; 38(5):477–489. PMID: 23822578.

54. Arkkila PE, Seppälä K, Färkkilä MA, Veijola L, Sipponen P. Helicobacter pylori eradication in the healing of atrophic gastritis: a one-year prospective study. Scand J Gastroenterol. 2006; 41(7):782–790. PMID: 16785190.

55. Lee H, Min BH, Lee JH, Son HJ, Kim JJ, Rhee JC, et al. Survival outcome associated with the screening interval for gastric cancer in Korea. Digestion. 2011; 84(2):142–148. PMID: 21525769.

56. Joo YE, Park HK, Myung DS, Baik GH, Shin JE, Seo GS, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia: a nationwide multicenter prospective study in Korea. Gut Liver. 2013; 7(3):303–310. PMID: 23710311.

57. Hwang YJ, Kim N, Kim SE, Baik GH, Lee JY, Park KS, et al. Change in the prevalences and risk factors of atrophic gastritis and intestinal metaplasia in Korea: multicenter clinical trials. Korean J Helicobacter Up Gastrointest Res. 2018; 18(4):247–257.

58. Kim HJ, Choi BY, Byun TJ, Eun CS, Song KS, Kim YS, et al. The prevalence of atrophic gastritis and intestinal metaplasia according to gender, age and Helicobacter pylori infection in a rural population. J Prev Med Public Health. 2008; 41(6):373–379. PMID: 19037166.

59. Kim N, Park RY, Cho SI, Lim SH, Lee KH, Lee W, et al. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol. 2008; 42(5):448–454. PMID: 18344895.

60. Nam JH, Choi IJ, Kook MC, Lee JY, Cho SJ, Nam SY, et al. OLGA and OLGIM stage distribution according to age and Helicobacter pylori status in the Korean population. Helicobacter. 2014; 19(2):81–89. PMID: 24617667.

61. Gawron AJ, Shah SC, Altayar O, Davitkov P, Morgan D, Turner K, et al. AGA technical review on gastric intestinal metaplasia-natural history and clinical outcomes. Gastroenterology. 2020; 158(3):705–731.e5. PMID: 31816300.

62. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008; 134(4):945–952. PMID: 18395075.

63. Song H, Ekheden IG, Zheng Z, Ericsson J, Nyrén O, Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk western population. BMJ. 2015; 351:h3867. PMID: 26215280.

64. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, Guilherme M, Barbosa J, Lomba-Viana H, et al. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol. 2004; 57(2):177–182. PMID: 14747445.

65. Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Ushiku T, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc. 2016; 84(4):618–624. PMID: 26995689.

66. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998; 338(11):727–734. PMID: 9494149.

67. Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998; 338(11):719–726. PMID: 9494148.

68. Karateev AE, Murav’ev IV. Omeprazole and misoprostol for NSAID-induced gastropathies: comparative efficiency of their short-term treatment. Klin Med (Mosk). 2001; 79(5):48–50.

69. Kairaluoma MI, Hentilae R, Alavaikko M, Kellosalo J, Stahlberg M, Jalovaara P, et al. Sucralfate versus placebo in treatment of non-ulcer dyspepsia. Am J Med. 1987; 83(3B):51–55. PMID: 3310629.

70. Skoubo-Kristensen E, Funch-Jensen P, Kruse A, Hanberg-Sørensen F, Amdrup E. Controlled clinical trial with sucralfate in the treatment of macroscopic gastritis. Scand J Gastroenterol. 1989; 24(6):716–720. PMID: 2683019.

71. Haruma K, Ito M, Kido S, Manabe N, Kitadai Y, Sumii M, et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002; 47(4):862–867. PMID: 11991622.

72. Kamada T, Sato M, Tokutomi T, Watanabe T, Murao T, Matsumoto H, et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. BioMed Res Int. 2015; 2015:865146. PMID: 26060821.

73. Han X, Jiang K, Wang B, Zhou L, Chen X, Li S. Effect of rebamipide on the premalignant progression of chronic gastritis: a randomized controlled study. Clin Drug Investig. 2015; 35(10):665–673.

74. Guslandi M. Comparison of sucralfate and ranitidine in the treatment of chronic nonerosive gastritis. A randomized, multicenter trial. Am J Med. 1989; 86(6A):45–48.

75. Kula Z, Rudziński J, Walasek L. Comparative evaluation of sucralfate (Venter) and cimetidine (Altramet) efficiency in treatment of chronic erosive gastritis. Przegl Lek. 1994; 51(2):73–76. PMID: 8058972.

76. Dhali GK, Garg PK, Sharma MP. Role of anti-Helicobacter pylori treatment in H. pylori-positive and cytoprotective drugs in H. pylori-negative, non-ulcer dyspepsia: results of a randomized, double-blind, controlled trial in Asian Indians. J Gastroenterol Hepatol. 1999; 14(6):523–528. PMID: 10385059.

77. Sakamoto C, Ogoshi K, Saigenji K, Narisawa R, Nagura H, Mine T, et al. Comparison of the effectiveness of geranylgeranylacetone with cimetidine in gastritis patients with dyspeptic symptoms and gastric lesions: a randomized, double-blind trial in Japan. Digestion. 2007; 75(4):215–224. PMID: 17971666.

78. Dewan B, Balasubramanian A. Troxipide in the management of gastritis: a randomized comparative trial in general practice. Gastroenterol Res Pract. 2010; 2010:758397. PMID: 21127703.

79. Civello IM, Amato A, Nazzari M, de Giovanni L. Sulglicotide versus sucralfate in the short-term treatment of non-ulcer dyspepsia: clinical and endoscopic evaluation. Curr Ther Res. 1988; 44(3):448–453.

80. Barbara L, Biasco G, Capurso L, Dobrilla G, Lalli A, Paganelli GM, et al. Effects of sucralfate and sulglycotide treatment on active gastritis and Helicobacter pylori colonization of the gastric mucosa in non-ulcer dyspepsia patients. Am J Gastroenterol. 1990; 5(9):1109–1113.

81. Psilogenis M, Nazzari M, Ferrari PA. A multicenter double-blind study of sulglycotide versus sucralfate in nonulcer dyspepsia. Int J Clin Pharmacol Ther Toxicol. 1990; 8(9):369–374.

82. Seol SY, Kim MH, Ryu JS, Choi MG, Shin DW, Ahn BO. DA-9601 for erosive gastritis: results of a double-blind placebo-controlled phase III clinical trial. World J Gastroenterol. 2004; 10(16):2379–2382. PMID: 15285023.

83. Jeong JJ, Choi MG, Choi H, Park JM, Oh JH, Jeon EJ, et al. Therapeutic efficacy of Gliptide^® Tab (sulglycotide 200 mg) in gastritis patients; phase IV study. Clin Endosc. 2007; 35:125–132.

84. Du Y, Li Z, Zhan X, Chen J, Gao J, Gong Y, et al. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. Dig Dis Sci. 2008; 53(11):2886–2895. PMID: 18288617.

85. Choi KS, Jung HY, Park JJ, Shim KN, Song HJ, Choi KD, et al. Therapeutic efficacy of Gliptide^® (sulglycotide) on gastritis - a double blind, randomized, active drug comparative, multi-center, phase IV study. Korean J Helicobacter Up Gastrointest Res. 2011; 11(3):185–192.

86. Du YQ, Su T, Hao JY, Wang BM, Chen MH, Li YM, et al. Gastro-protecting effect of gefarnate on chronic erosive gastritis with dyspeptic symptoms. Chin Med J (Engl). 2012; 25(16):2878–2884.

87. Moon JS, Park SH, Park JJ, Lee SW, Lee DH, Lee YC, et al. Therapeutic efficacy of Gliptide (sulglycotide 200 mg): a double blinded, randomized, active drug comparative, multicenter study. Korean J Helicobacter Up Gastrointest Res. 2013; 13(3):173–181.